Skip to main content
. 2021 Apr 22;10(5):977. doi: 10.3390/cells10050977

Figure 7.

Figure 7

Response rates in the high-risk (high) versus the low-risk (low) groups in advanced melanoma patients treated with anti- PD-1 monotherapy based on the 15 lncRNAs signature. (A) Response rates based on the 15 lncRNAs signature in advanced melanoma patients treated with anti-PD-1 monotherapy in the training cohort. (B) Response rates based on the 15 lncRNAs signature in advanced melanoma patients treated with anti-PD-1 monotherapy in the validation cohort. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.